HC Wainwright & Co. Reiterates Buy on AEON Biopharma, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on AEON Biopharma, maintaining a price target of $5.
October 01, 2024 | 10:20 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on AEON Biopharma, maintaining a price target of $5. This suggests confidence in AEON's potential for growth.
The reiteration of a Buy rating and maintenance of a $5 price target by HC Wainwright & Co. indicates a positive outlook on AEON Biopharma's stock. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100